Patents by Inventor Rajneesh Taneja

Rajneesh Taneja has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230310276
    Abstract: Provided are methods of preparing a homogeneous mixture from a solid dosage form in settings including a point of care setting. The methods include obtaining a solid dosage form comprising a drug product, adding the solid dosage form to a container having at least one flexible section, adding a liquid to the container, mixing the solid dosage form with the liquid to disperse, disintegrate, suspend, and/or dissolve the solid dosage form thereby creating a homogeneous mixture. Also provided are containers and devices for use in such methods.
    Type: Application
    Filed: August 30, 2021
    Publication date: October 5, 2023
    Inventors: Rajneesh TANEJA, Joseph Anthony SCARIM
  • Patent number: 11179375
    Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: November 23, 2021
    Assignee: ZINFANDEL PHARMACEUTICALS, INC.
    Inventors: Allen D. Roses, Rajneesh Taneja
  • Publication number: 20190151298
    Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
    Type: Application
    Filed: January 28, 2019
    Publication date: May 23, 2019
    Applicants: Takeda Pharmaceutical Company Limited, Zinfandel Pharmaceuticals, Inc.
    Inventors: Allen D. Roses, Rajneesh Taneja
  • Patent number: 9937157
    Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: April 10, 2018
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad
  • Patent number: 9889152
    Abstract: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: February 13, 2018
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Majid Vakilynejad
  • Publication number: 20170348231
    Abstract: Provided herein is an optimized method of enhancing endogenous gonadotropins and testosterone/estrogen production and concentrations comprising administration of a therapeutically effective amount of at least one GnRH agonist to a patient in need of such treatment. A method and dosing regimen is also described for delivery across the mucosa of the oral cavity for maximizing absorption and delivery, limiting systemic exposure and unwanted side effects, effectuating a sustained increase in concentrations of sex hormones and providing a non-invasive delivery that does not require inpatient visits. The method described benefits conditions such as hypogonadism in men due to aging or disease and symptoms related to menopause in women.
    Type: Application
    Filed: June 2, 2016
    Publication date: December 7, 2017
    Applicant: NHTherapeutics INC
    Inventors: Rajneesh Taneja, Aldemar B. De Groot
  • Publication number: 20170319565
    Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
    Type: Application
    Filed: May 22, 2017
    Publication date: November 9, 2017
    Applicants: Takeda Pharmaceutical Company Limited, Zinfandel Pharmaceuticals, Inc.
    Inventors: Allen D. Roses, Rajneesh Taneja
  • Patent number: 9724339
    Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: August 8, 2017
    Assignees: Zinfandel Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited
    Inventors: Allen D. Roses, Rajneesh Taneja
  • Publication number: 20160317505
    Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.
    Type: Application
    Filed: January 29, 2016
    Publication date: November 3, 2016
    Applicant: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad
  • Publication number: 20160058788
    Abstract: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
    Type: Application
    Filed: November 11, 2015
    Publication date: March 3, 2016
    Inventors: Rajneesh Taneja, Majid Vakilynejad
  • Patent number: 9248119
    Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: February 2, 2016
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad
  • Patent number: 9238029
    Abstract: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: January 19, 2016
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Majid Vakilynejad
  • Publication number: 20160000769
    Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
    Type: Application
    Filed: June 15, 2015
    Publication date: January 7, 2016
    Applicants: Takeda Pharmaceutical Company Limited, Zinfandel Pharmaceuticals, Inc.
    Inventors: Allen D. Roses, Rajneesh Taneja
  • Patent number: 9102666
    Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: August 11, 2015
    Assignees: ZINFANDEL PHARMACEUTICALS, INC., TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Allen D. Roses, Rajneesh Taneja
  • Publication number: 20130245071
    Abstract: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
    Type: Application
    Filed: April 30, 2013
    Publication date: September 19, 2013
    Inventors: Rajneesh Taneja, Majid Vakilynejad
  • Patent number: 8461187
    Abstract: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: June 11, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Majid Vakilynejad
  • Publication number: 20120252848
    Abstract: Provided herein are formulations of acid labile drugs, such as proton pump inhibitors (PPI). The formulations comprise a PPI and a liquid vehicle typically having a pH greater than 6.5 and a viscosity sufficient to maintain a uniform suspension of the PPI for 15 minutes.
    Type: Application
    Filed: May 17, 2012
    Publication date: October 4, 2012
    Inventor: Rajneesh Taneja
  • Publication number: 20120184584
    Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
    Type: Application
    Filed: January 9, 2012
    Publication date: July 19, 2012
    Inventors: Allen D. Roses, Rajneesh Taneja
  • Publication number: 20120142737
    Abstract: A method for treating gastric acid disorders with a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal; and a pharmaceutical composition of a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal are disclosed. A presently preferred proton pump inhibitor is lansoprazole, a presently preferred bicarbonate salt is sodium bicarbonate, and a presently preferred carbonate salt is sodium carbonate. The composition is a fast-acting formulation which reduces the undesirable belching associated with proton pump inhibitor formulations that contain high doses of sodium bicarbonate.
    Type: Application
    Filed: March 21, 2011
    Publication date: June 7, 2012
    Inventors: Rajneesh Taneja, Pramod Gupta
  • Publication number: 20110311620
    Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.
    Type: Application
    Filed: June 15, 2011
    Publication date: December 22, 2011
    Applicant: Takeda Pharmaceuticals North America, Inc.
    Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad